Prognostic value of sST2 and galectin-3 for death relative to renal function in patients hospitalized for heart failure

Biomarkers in Medicine

Volumn 9, Issue 5, 2015, Pages 433-441

  Zhang, Rongcheng ^a   Zhang, Yuhui ^a   An, Tao ^a   Guo, Xiao ^a   Yin, Shijie ^a   Wang, Yunhong ^a   Januzzi, James L ^b   Cappola, Thomas P ^c   Zhang, Jian ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Biomarker; Cardiac remodeling; Death; eGFR; Galectin 3; Heart failure; NT proBNP; Prognosis; Renal function; sST2

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; GALECTIN 3; SOLUBLE ST2; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL PATIENT; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; MODERATE RENAL IMPAIRMENT; MOLECULAR DYNAMICS; MORTALITY; NEW YORK HEART ASSOCIATION CLASS; PREDICTIVE VALUE; PROGNOSIS; RISK FACTOR; AGED; BLOOD; KIDNEY; KIDNEY FUNCTION TEST; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; AGED; BIOMARKERS; FEMALE; GALECTIN 3; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, CELL SURFACE;

EID: 84929583765     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.15.12     Document Type: Article

References (25)

1. Hillege HL, Nitsch D, Pfeffer MA et al. Renal function as axpredictor of outcome in a broad spectrum of patients with heart failure. Circulation 113(5), 671-678 (2006).
2. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 109(8), 1004-1009 (2004).
3. Shah RV, Januzzi JL Jr. Soluble ST2 and Galectin-3 in Heart Failure. Clin. Lab. Med. 34(1), 87-97 (2014).
4. Bao YS, Na SP, Zhang P et al. Characterization of interleukin-33 and soluble ST2 in serum and their association with disease severity in patients with chronic kidney disease. J. Clin. Immunol. 32(3), 587-594 (2012).
5. Gopal DM, Kommineni M, Ayalon N et al. Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. J. Am. Heart Assoc. 1(5), e000760 (2012). •• First study to investigate whether the relationship between renal function and galectin-3 is influenced by the presence or absence of clinical heart failure.
6. Bayes-Genis A, Zamora E, de Antonio M et al. Soluble ST2 serum concentration and renal function in heart failure. J. Card. Fail. 19(11), 768-775 (2013). • First study to evaluate the association between prognostic value of sST2 and renal function.
7. Zhang R, Zhang Y, Zhang J et al. the prognostic value of plasma soluble ST2 in hospitalized Chinese patients with heart failure. PLoS ONE 9(10), e110976 (2014).
8. Zhang Y, Zhang R, An T et al. The utility of galectin-3 for predicting cause-specific death in hospitalized patients with heart failure. J. Card. Fail. 21(1), 51-59 (2015).
9. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150(9), 604-612 (2009). • A new equation more accurately to estimate glomerular filtration rate than Modification of Diet in Renal Disease (MDRD) equation.
10. Levey AS, Coresh J, Balk E et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann. Intern. Med. 139(2), 137-147 (2003).
11. Sanada S, Hakuno D, Higgins LJ et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest. 117(6), 1538-1549 (2007). •• First study to explore the role of ST2 in the myocardium.
12. de Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Curr. Heart Fail. Rep. 7(1), 1-8 (2010).
13. Kumar S, Tzimas MN, Griswold DE, Young PR. Expression of ST2, an interleukin-1 receptor homologue, is induced by proinflammatory stimuli. Biochem. Biophys. Res. Commun. 235(3), 474-478 (1997).
14. Barondes SH, Cooper DN, Gitt MA, Leffler H. Galectins. Structure and function of a large family of animal lectins. J. Biol. Chem. 269(33), 20807-20810 (1994).
15. Henderson NC, Mackinnon AC, Farnworth SL et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc. Natl Acad. Sci. USA 103(13), 5060-5065 (2006).
16. Henderson NC, Mackinnon AC, Farnworth SL et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am. J. Pathol. 172(2), 288-298 (2008). • Demonstrates for the first time that galectin-3 expression and secretion by macrophages is a major mechanism to the promotion of renal fibrosis.
17. Wang L, Friess H, Zhu Z et al. Galectin-1 and galectin-3 in chronic pancreatitis. Lab. Invest. 80(8), 1233-1241 (2000).
18. Dieplinger B, Januzzi JL Jr, Steinmair M et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma-the Presage ST2 assay. Clin. Chim. Acta. 409(1-2), 33-40 (2009). • Evaluates the determination of sST2 with a novel Presage ST2 assay.
19. O'Seaghdha CM, Hwang SJ, Ho JE et al. Elevated galectin-3 precedes the development of CKD. J. Am. Soc. Nephrol. 24(9), 1470-1477 (2013). • Found galectin-3 are associated with increased risks of chronic kidney disease incident in the community.
20. de Boer RA, Lok DJ, Jaarsma T et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann. Med. 43(1), 60-68 (2011).
21. Lopez-Andres N, Rossignol P, Iraqi W et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur. J. Heart Fail. 14(1), 74-81 (2012).
22. Bayes-Genis A, de Antonio M, Vila J et al. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. J. Am. Coll. Cardiol. 63(2), 158-166 (2014). • First study to compare the predictive power of ST2 and galectin-3 in patients with heart failure.
23. Broch K, Ueland T, Nymo SH et al. Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology. Eur. J. Heart Fail. 14(3), 268-277 (2012).
24. Ahmad T, Fiuzat M, Neely B et al. Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure. JACC Heart Fail. 2(3), 260-268 (2014).
25. Meijers WC, Januzzi JL, deFilippi C et al. Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials. Am. Heart J. 167(6), 853-860, e854 (2014).